D&D PharmaTech Co.

D&D Pharmatech Inc. is a South Korean company engaged in the research, development, and manufacturing of pharmaceuticals. Its pipeline includes oral peptides such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 for obesity, and injectable peptides including DD01 for MASH, NLY12 and DD15 for obesity, and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases. The company also develops TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis; NLY02, an oral small molecule for Parkinson's and Alzheimer's diseases; P4M01 for anti-microbial peptide indications; PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation. Founded in 2014, it is based in Seongnam-si, South Korea.